ストックスクリーナーアプリを入手
26.05
1.56%
0.40
アフターアワーズ：
25.49
-0.56
-2.15%
Uniqure N V (QURE) 最新ニュース
Pullback Watch: Will uniQure NV benefit from geopolitical trendsSwing Trade & Weekly Chart Analysis and Guides - baoquankhu1.vn
How Early AMT-191 Gene Therapy Signals Will Impact uniQure (QURE) Investors - simplywall.st
Discipline and Rules-Based Execution in QURE Response - Stock Traders Daily
uniQure reports promising data from Fabry disease gene therapy trial By Investing.com - Investing.com Nigeria
UniQure's AMT-191 Sustains Key Enzyme Activity In Fabry Disease In Phase I/IIa Trial; Stock Up - Nasdaq
Uniqure stock rises after AMT-191 gene therapy shows promising Fabry results - Investing.com
uniQure (QURE) Shares Promising Data on Gene Therapy for Fabry D - GuruFocus
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease - The Manila Times
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa - GlobeNewswire
uniQure (NASDAQ:QURE) Stock Price Up 8.6%What's Next? - MarketBeat
Here’s Why uniQure (QURE) Declined in Q4 - Yahoo Finance
Aug Opening: Why is uniQure NV stock going downWeekly Risk Summary & Fast Gain Stock Trading Tips - baoquankhu1.vn
uniQure (QURE) Is Down 9.4% After FDA Deems AMT-130 Data Insufficient for BLA Filing - Sahm
Stock Recap: Is uniQure NV stock risky to hold nowQuarterly Earnings Report & Expert Approved Trade Ideas - baoquankhu1.vn
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourage - GuruFocus
Update Recap: Will uniQure NV benefit from geopolitical trendsJuly 2025 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ - marketscreener.com
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
Aug Swings: Can uniQure NV continue delivering strong returnsInflation Watch & Verified Swing Trading Watchlists - baoquankhu1.vn
Privium Fund Management B.V. Sells 61,486 Shares of uniQure N.V. $QURE - MarketBeat
UniQure N.V. (QURE) Stock Analysis: A Biotech Player With 127.68% Potential Upside - DirectorsTalk Interviews
QURE Investigation Alert: Kessler Topaz Meltzer & Check, - GlobeNewswire
Geopolitics Watch: Can uniQure NV continue delivering strong returnsQuarterly Portfolio Review & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
uniQure (NASDAQ:QURE) Stock Rating Upgraded by Barclays - MarketBeat
Barclays Downgrades UniQure NV(QURE.US) to Hold Rating, Raises Target Price to $31 - 富途牛牛
Barclays Initiates Coverage of uniQure N.V. (QURE) with Equal-Weight Recommendation - Nasdaq
What Analysts Are Saying About uniQure Stock - Benzinga
Barclays Initiates Coverage on uniQure (QURE) with Equal-Weight Rating | QURE Stock News - GuruFocus
Barclays Initiates Coverage on uniQure N.V With Equal Weight Rating, $31 Price Target - marketscreener.com
Behavioral Patterns of QURE and Institutional Flows - Stock Traders Daily
Does uniQure N.V. have strong fundamentalsPortfolio Gains Summary & Safe Capital Growth Tips - mfd.ru
Trend Review: Is uniQure NV stock forming a triangle pattern2025 Year in Review & Safe Capital Growth Plans - baoquankhu1.vn
Genmab pauses enrollment in early ADC trial acquired from ProfoundBio - European Biotechnology Magazine
Retail Trends: Why is uniQure NV stock going downJuly 2025 Analyst Calls & Fast Gain Swing Alerts - baoquankhu1.vn
Huntington’s Advocates Press FDA to Approve UniQure’s Treatment - Bloomberg.com
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Shares Gap UpStill a Buy? - MarketBeat
uniQure N.V. $QURE Shares Sold by SG Americas Securities LLC - MarketBeat
Huntington's Disease Market Poised for Transformation Through - openPR.com
UNIQURE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70 - 富途资讯
QURE INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving uniQURE N.V. - ACCESS Newswire
Here’s Why uniQure (QURE) Fell in Q3 - Insider Monkey
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - FinancialContent
uniQure N.V. (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Prime Publishers, Inc.
Short Interest in uniQure N.V. (NASDAQ:QURE) Rises By 33.8% - MarketBeat
(QURE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
QURE Investigation Reminder: Kessler Topaz Meltzer & - GlobeNewswire
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
uniQure (NASDAQ:QURE) Shares Up 5%Here's What Happened - MarketBeat
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - MSN
Downgrade Watch: Will uniQure NV stock benefit from M ALong Setup & Daily Market Momentum Tracking - baoquankhu1.vn
Robert Gut Sells 25,613 Shares of uniQure (NASDAQ:QURE) Stock - MarketBeat
RSI Check: Can uniQure NV continue delivering strong returnsJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Health Check: How Prudently Does UniQure (NASDAQ:QURE) Use Debt? - 富途牛牛
uniQure stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
Cantor Fitzgerald Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $55 - 富途资讯
uniQure stock rating reiterated at Overweight by Cantor Fitzgerald By Investing.com - Investing.com Australia
0.10%
7.16%
大文字化:
|
ボリューム (24 時間):